297 related articles for article (PubMed ID: 31141112)
1. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
[TBL] [Abstract][Full Text] [Related]
4. The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Showalter TN; Zhan T; Anne PR; Chervoneva I; Mitchell EP; Yeo CJ; Rosato EL; Kennedy EP; Berger AC
J Gastrointest Surg; 2011 Aug; 15(8):1411-6. PubMed ID: 21523621
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis.
Kamarajah SK
Clin Transl Oncol; 2018 Sep; 20(9):1212-1218. PubMed ID: 29497964
[TBL] [Abstract][Full Text] [Related]
6. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
Patel M; Uboha NV
Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.
Palta M; Patel P; Broadwater G; Willett C; Pepek J; Tyler D; Zafar SY; Uronis H; Hurwitz H; White R; Czito B
Ann Surg Oncol; 2012 May; 19(5):1535-40. PubMed ID: 22045467
[TBL] [Abstract][Full Text] [Related]
8. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
[TBL] [Abstract][Full Text] [Related]
9. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Ramaswamy A; Bhandare M; Bal M; Shrirangwar S; Kataria P; Majumdar S; Swami R; Rohila J; Chaudhari V; Mandavkar S; Chavan N; Shrikhande SV; Ostwal V
HPB (Oxford); 2020 Mar; 22(3):376-382. PubMed ID: 31405778
[TBL] [Abstract][Full Text] [Related]
10. Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Colussi O; Voron T; Pozet A; Hammel P; Sauvanet A; Bachet JB; Vaillant JC; Rougier P; Nordlinger B; Berger A; Coriat R; Dousset B; Malka D; André T; Paye F; Aparicio T; Locher C; Cojean Zeleck D; Tchinou L; Bonnetain F; Taieb J
Eur J Surg Oncol; 2015 Apr; 41(4):520-6. PubMed ID: 25680954
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.
Kim WS; Choi DW; Choi SH; Heo JS; You DD; Lee HG
J Surg Oncol; 2012 Mar; 105(3):266-72. PubMed ID: 21882202
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study.
Bolm L; Ohrner K; Nappo G; Rückert F; Zimmermann C; Rau BM; Petrova E; Honselmann KC; Lapshyn H; Bausch D; Weitz J; Sandini M; Keck T; Zerbi A; Distler M; Wellner UF
Pancreatology; 2020 Apr; 20(3):433-441. PubMed ID: 31987649
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
14. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
Kim K; Chie EK; Jang JY; Kim SW; Han SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
Clin Transl Oncol; 2012 May; 14(5):391-5. PubMed ID: 22551547
[TBL] [Abstract][Full Text] [Related]
18. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?
Westgaard A; Pomianowska E; Clausen OP; Gladhaug IP
Ann Surg Oncol; 2013 Feb; 20(2):430-9. PubMed ID: 22956064
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the two histological subtypes of ampullary adenocarcinoma: a retrospective study.
Xu ZY; Guan J; Zhang ZY; Liu DW; Li XD; Zhou ZQ
Cir Cir; 2024; 92(2):159-164. PubMed ID: 38782386
[TBL] [Abstract][Full Text] [Related]
20. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.
Westgaard A; Tafjord S; Farstad IN; Cvancarova M; Eide TJ; Mathisen O; Clausen OP; Gladhaug IP
BMC Cancer; 2008 Jun; 8():170. PubMed ID: 18547417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
